MEI End Period Cash Flow from 2010 to 2025

MEIP Stock  USD 2.43  0.03  1.22%   
MEI Pharma End Period Cash Flow yearly trend continues to be relatively stable with very little volatility. End Period Cash Flow is likely to drop to about 3.2 M. During the period from 2010 to 2025, MEI Pharma End Period Cash Flow destribution of quarterly values had range of 32.4 M from its regression line and mean deviation of  5,439,383. View All Fundamentals
 
End Period Cash Flow  
First Reported
2002-06-30
Previous Quarter
M
Current Value
23.7 M
Quarterly Volatility
8.1 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MEI Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MEI Pharma's main balance sheet or income statement drivers, such as Interest Expense of 310.3 K, Selling General Administrative of 28.1 M or Total Revenue of 78.8 M, as well as many indicators such as Price To Sales Ratio of 0.32, Dividend Yield of 0.49 or PTB Ratio of 0.63. MEI financial statements analysis is a perfect complement when working with MEI Pharma Valuation or Volatility modules.
  
Check out the analysis of MEI Pharma Correlation against competitors.
To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.

Latest MEI Pharma's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of MEI Pharma over the last few years. It is MEI Pharma's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MEI Pharma's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

MEI End Period Cash Flow Regression Statistics

Arithmetic Mean11,834,705
Geometric Mean9,751,893
Coefficient Of Variation66.84
Mean Deviation5,439,383
Median10,837,000
Standard Deviation7,910,826
Sample Variance62.6T
Range32.4M
R-Value(0.42)
Mean Square Error55.3T
R-Squared0.18
Significance0.11
Slope(697,047)
Total Sum of Squares938.7T

MEI End Period Cash Flow History

20253.2 M
20243.3 M
20233.7 M
202216.9 M
202115.7 M
20208.5 M
201912.3 M

About MEI Pharma Financial Statements

MEI Pharma shareholders use historical fundamental indicators, such as End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although MEI Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in MEI Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on MEI Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
End Period Cash Flow3.3 M3.2 M

Additional Tools for MEI Stock Analysis

When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.